Jason M. K. Ho

Regression of <i>BRAF</i>V600E mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: a report of two cases

Peter Yat Ming Woo, Tai‐Chung Lam, Jenny Kan-Suen Pu et al. · Oncotarget · 2019 · 38 citations · Full text

A Comparative Analysis of the Usefulness of Survival Prediction Models for Patients with Glioblastoma in the Temozolomide Era: The Importance of Methylguanine Methyltransferase Promoter Methylation, Extent of Resection, and Subventricular Zone Location

Peter Y. M. Woo, Jason M. K. Ho, Sandy Lam et al. · World Neurosurgery · 2018 · 23 citations

Neuro-oncology, Medicine, Prognosis +10

Overshunting-associated myelopathy: report of 2 cases

Jason M. K. Ho, Hing-Yuen Law, Shing-Chau Yuen et al. · Neurosurgical FOCUS · 2016 · 18 citations · Full text

Spinal Cord Injury, Overshunting-associated Myelopathy, Intracranial Shunts +11

Patterns of care and survival of Chinese glioblastoma patients in the temozolomide era: a Hong Kong population-level analysis over a 14-year period

Peter Y. M. Woo, Stephen S. Yau, Tai‐Chung Lam et al. · Neuro-Oncology Practice · 2022 · 16 citations · Full text

Determining a cut-off residual tumor volume threshold for patients with newly diagnosed glioblastoma treated with temozolomide chemoradiotherapy: A multicenter cohort study

Peter Yat Ming Woo, Jason M. K. Ho, Teresa P K Tse et al. · Journal of Clinical Neuroscience · 2019 · 14 citations

Neuro-oncology, Oncologic Imaging, Temozolomide Chemoradiotherapy +9